<DOC>
	<DOC>NCT02375971</DOC>
	<brief_summary>The purpose of this study is to determine if intravitreal ranibizumab is superior to laser ablation therapy in the treatment of retinopathy of prematurity (ROP).</brief_summary>
	<brief_title>RAINBOW Study: RAnibizumab Compared With Laser Therapy for the Treatment of INfants BOrn Prematurely With Retinopathy of Prematurity</brief_title>
	<detailed_description />
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Premature Birth</mesh_term>
	<mesh_term>Retinopathy of Prematurity</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Preterm infants with a birth weight of less than 1500 g Bilateral ROP with 1 of the following retinal findings in each eye: Zone I, stage 1+, 2+, 3 or 3+ disease, or Zone II, stage 3+ disease, or Aggressive posterior ROP Have received any previous surgical or nonsurgical treatment for ROP (e.g., ablative laser therapy or cryotherapy, vitrectomy) Have been previously exposed to any intravitreal or systemic antiVEGF agent (either the patient or the mother during this child's pregnancy) Have ocular structural abnormalities that are assessed by the Investigator to have a clinically significant impact on study assessments Have active ocular infection within 5 days before or on the day of first investigational treatment Have any other medical conditions or clinically significant comorbidities or personal circumstances that are assessed by the Investigator to have a clinically relevant impact on study participation, any of the study procedures, or on efficacy assessments Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>intravitreal ranibizumab</keyword>
	<keyword>laser ablation therapy</keyword>
	<keyword>retinopathy of prematurity</keyword>
	<keyword>preterm infants</keyword>
	<keyword>RAINBOW</keyword>
</DOC>